Aberdeen Group plc Sells 112,582 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Aberdeen Group plc reduced its stake in Arrowhead Pharmaceuticals by 10.5%, selling 112,582 shares during the second quarter, leaving them with approximately 960,245 shares valued at $15.17 million.
• Multiple institutional investors are increasing their holdings, with GAMMA Investing raising its stake by 297.6% in the first quarter, now owning 2,175 shares.
• Analysts have mixed ratings on Arrowhead Pharmaceuticals, with a consensus target price of $43.14, and recent price targets set as high as $80.00 while Royal Bank of Canada lowered theirs from $40.00 to $38.00.

Aberdeen Group plc decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 10.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 960,245 shares of the biotechnology company's stock after selling 112,582 shares during the period. Aberdeen Group plc owned about 0.70% of Arrowhead Pharmaceuticals worth $15,172,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ARWR. GAMMA Investing LLC raised its stake in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,628 shares during the period. CWM LLC grew its position in shares of Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 2,523 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Arrowhead Pharmaceuticals by 29.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock valued at $84,000 after purchasing an additional 1,214 shares during the last quarter. KBC Group NV grew its position in shares of Arrowhead Pharmaceuticals by 40.8% in the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 2,132 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the first quarter valued at approximately $133,000. Institutional investors own 62.61% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ARWR shares. Royal Bank Of Canada reduced their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. TD Cowen raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. B. Riley raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Chardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Down 0.8%

ARWR opened at $35.96 on Wednesday. The firm has a market capitalization of $4.97 billion, a P/E ratio of -28.09 and a beta of 1.13. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $39.42. The company has a fifty day moving average price of $27.38 and a 200-day moving average price of $19.25.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The company had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the previous year, the company posted ($1.38) earnings per share. Equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the company's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the sale, the insider directly owned 212,122 shares in the company, valued at $7,424,270. This represents a 8.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 60,000 shares of company stock worth $1,725,000 in the last ninety days. Corporate insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.